top of page
Multigene Panel Genetic Testing for Breast Cancer: Beyond BRCA — Who Should Be Tested?

Multigene Panel Genetic Testing for Breast Cancer: Beyond BRCA — Who Should Be Tested?

ป้าหมอนุช
2 hours ago
4 min read

Multigene panel genetic testing examines blood or saliva for inherited mutations in many genes at once — not only BRCA1 and BRCA2 but also PALB2, TP53, CHEK2, ATM, PTEN, CDH1 and others. Results help choose treatment (such as PARP inhibitors or the type of surgery), plan screening, and allow close relatives to be tested. At Namarak Hospital, we provide genetic counseling in-house before and after testing, send samples to internationally accredited laboratories, and plan care based on the results.

Key genes linked to breast cancer

  • High risk: BRCA1, BRCA2, PALB2, TP53 (Li-Fraumeni), PTEN (Cowden), CDH1 (lobular breast cancer and gastric cancer), STK11

  • Moderate risk: CHEK2, ATM, BARD1, RAD51C, RAD51D (the last two also raise ovarian cancer risk)

  • Each gene carries different risks and recommendations, so panel results must be interpreted by specialists — see BRCA genes and family history

Who should be tested?

People already diagnosed with breast cancer

The two main international guidelines use slightly different criteria.

  • ASCO–SSO (2024): offer BRCA1/2 testing to all patients newly diagnosed at age 65 or younger (stage I–III or de novo metastatic), and to those over 65 who meet criteria, such as PARP inhibitor candidates, triple-negative disease, men, or a suggestive personal or family history

  • NCCN (2026): test those diagnosed at age 50 or younger, or at any age with any of the following

  • Triple-negative breast cancer

  • Male breast cancer, or a second breast cancer (same or opposite breast)

  • A close relative with breast cancer (especially at age 50 or younger), ovarian, pancreatic or high-risk prostate cancer

  • Lobular breast cancer with a personal or family history of diffuse gastric cancer

  • Ancestry with a high mutation rate, such as Ashkenazi Jewish

  • When the result would affect treatment, such as PARP inhibitors in advanced disease or adjuvant olaparib in high-risk early disease

In practice, the breast surgeon will discuss with you whether the result would change your treatment or your family’s care.

People without cancer

  • A close relative already found to carry a mutation — testing for that specific gene is possible

  • A strong family history, such as several relatives with breast or ovarian cancer or cancer at a young age

  • Where possible, the relative who has had cancer should be tested first for the most accurate interpretation

Three possible results

  • Positive (pathogenic / likely pathogenic) — a mutation that increases risk; screening and prevention are planned, and relatives are advised to be tested

  • Negative — no mutation found in the genes tested, but care still follows your family history

  • VUS (variant of uncertain significance) — a change whose meaning is not yet known; it is not used for treatment or surgical decisions, and most are later reclassified as harmless

How results change care

  • Surgery: BRCA1/BRCA2 carriers may consider bilateral risk-reducing mastectomy, or removal of the ovaries and fallopian tubes at the recommended age; TP53 carriers should avoid radiation where possible

  • Drugs: BRCA mutations — PARP inhibitors (olaparib, talazoparib)

  • Screening: yearly breast MRI with mammography from a young age; under the Thai guideline, mammography with ultrasound may be alternated with MRI — see Breast MRI

  • Family: parents, siblings and children have a 50% chance of carrying the same mutation and should be offered counseling and testing

What to know before testing

  • Genetic counseling before and after testing helps you understand the results and their impact on your family

  • A single blood or saliva sample is sent to an internationally accredited laboratory; results take about 2–4 weeks

  • Results are protected personal information, and you decide how to share them with relatives

  • Costs and coverage vary; our team will explain them before testing

Frequently asked questions (FAQ)

Is testing BRCA alone enough?

Multigene panels are now recommended, because mutations in other genes such as PALB2, CHEK2, ATM and TP53 are not uncommon, and some change treatment or screening.

Should I have genetic testing after a breast cancer diagnosis?

ASCO–SSO 2024 recommends offering BRCA1/2 testing to everyone newly diagnosed at age 65 or younger, while NCCN recommends testing those diagnosed at 50 or younger, or at any age with risk features such as triple-negative disease or a family history. Your doctor will decide with you individually.

What does a VUS result mean?

It is a gene change of unknown significance. It is not used for surgical or treatment decisions; care follows your family history, and the variant may be reclassified in the future.

If I carry a mutation, will my children get cancer?

Each child has a 50% chance of inheriting it, but carrying a mutation does not mean cancer is certain. Knowing early allows screening and prevention to be planned.

How does inherited gene testing differ from Oncotype DX?

Inherited gene testing uses blood to assess family risk, while Oncotype DX tests genes in the tumor to guide chemotherapy decisions.

About Namarak Hospital

Namarak Hospital is a specialized breast and breast cancer hospital in Bangkok, providing complete care in one place — from diagnosis with 3D mammography, ultrasound, automated breast ultrasound (ABUS) and biopsy to comprehensive breast cancer treatment, including breast-conserving and reconstructive surgery, intraoperative radiotherapy (IORT), chemotherapy, targeted therapy and endocrine therapy, planned by a multidisciplinary team according to the latest international guidelines. See Breast cancer treatment: a complete guide, contact us on LINE, tel. +66 2 059 0245, or our Second Opinion service.

Related articles

References

  • Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline. J Clin Oncol 2024;42:584–604

  • NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic and Prostate, 2026

  • Tung NM, et al. Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline. J Clin Oncol 2020;38:2080–106

  • Tutt ANJ, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer (OlympiA). N Engl J Med 2021;384:2394–405

  • Thai Clinical Practice Guideline for Breast Cancer, Association of Thai Breast Disease Society and National Cancer Institute of Thailand

Medically reviewed by: Namarak Hospital medical team · Last checked: 17 November 2026 · This information is for general education and is not individual medical advice. Please consult your doctor for diagnosis and treatment suited to you.

Comments


Link to the Namarak Hospital medical team profiles
bottom of page